Shigeto Kubo

TL;DR: It is shown that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFRand HER2 mutants, including erlotinib-resistant isoforms.

TL;DR: A mouse model with doxycycline-inducible expression of a mutant EGFR containing both L858R, an erlotinib-sensitizing mutation, and the T790M resistance mutation resulted in significant regression of both types of lung tumors.

TL;DR: It is demonstrated that inducible expression of the most common HER2 mutant (HER2YVMA) in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles.

TL;DR: Hsp90 inhibition overcomes limitations in vitro and depletes cells of EGFR, other RTKs, and phospho-Akt and inhibits mTOR signaling whether or not T790M is present and suggest that Hsp90 inhibitors may be effective in T790m-expressing cells and offer an alternative therapeutic strategy for this subset of lung cancers.

TL;DR: The hypothesis that EGFR-targeting monoclonal antibody mAb806 may lead to significant advancements in the treatment of the population of NSCLC patients with these 2 classes of EGFR mutations is supported.